Staging systems for papillary thyroid carcinoma: A review and comparison

Annals of Surgery

Volumn 245, Issue 3, 2007, Pages 366-378

  Lang, Brian Hung Hin ^a   Lo, Chung Yau ^a,c   Chan, Wai Fan ^a   Lam, King Yin ^b   Wan, Koon Yat ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b GRIFFITH UNIVERSITY   (Australia)

^c QUEEN MARY HOSPITAL   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131;

AGE METASTASES EXTENT AND SIZE SYSTEM; ANKARA ONCOLOGY TRAINING AND RESEARCH HOSPITAL SYSTEM; CANCER INSTITUTE HOSPITAL SYSTEM; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL CLASS SYSTEM; EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER SYSTEM; GRADE AGE METASTASES EXTENT SIZE SYSTEM; HUMAN; INTERMETHOD COMPARISON; METASTASES AGE COMPLETENESS OF SURGERY INVASION AND SIZE SYSTEM; NATIONAL THYROID CANCER TREATMENT COOPERATIVE STUDY SYSTEM; NOGUCHI SYSTEM; OHIO STATE UNIVERSITY SYSTEM; PAPILLARY CARCINOMA; PREDICTIVE VALIDITY; PRIORITY JOURNAL; REVIEW; THYROID CARCINOMA; UNIVERSITY OF ALABAMA AND MD ANDERSON SYSTEM; UNIVERSITY OF MUNSTER SYSTEM; UNIVERSITY OF MURCIA SYSTEM;

CARCINOMA, PAPILLARY; FEMALE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; RISK ASSESSMENT; SURVIVAL ANALYSIS; THYROID NEOPLASMS; THYROIDECTOMY;

EID: 34247614170     PISSN: 00034932     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.sla.0000250445.92336.2a     Document Type: Review

References (50)

1. Sherman SI. Thyroid carcinoma. Lancet. 2003;361:501-511.
2. Lang BH, Lo CY, Chan WF, et al. Prognostic factors in papillary and follicular thyroid carcinoma: their implications for cancer staging. Ann Surg Oncol. In press.
3. Cancer incidence and mortality in Hong Kong from 1983 to 2002. Hong Kong Cancer Registry, Hong Kong. Available at: http://www3.ha.org.hk/cancereg/stat. asp. Accessed April 25, 2006.
4. Haselkorn T, Bernstein L, Preston-Martin S, et al. Descriptive epidemiology of thyroid cancer in Los Angeles County, 1972-1995. Cancer Causes Control. 2000;11:163-170.
5. Hodgson NC, Button J, Solorzano CC. Thyroid cancer: is the incidence still increasing? Ann Surg Oncol. 2004;11:1093-1097.
6. Reynolds RM, Weir J, Stockton DL, et al. Changing trends in incidence and mortality of thyroid cancer in Scotland. Clin Endocrinol (Oxf). 2005;62:156-162.
7. Burgess JR, Tucker P. Incidence trends for papillary thyroid carcinoma and their correlation with thyroid surgery and thyroid fine-needle aspirate cytology. Thyroid. 2006;16:47-53.
8. Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States. JAMA. 2006;295:2164-2167.
9. Mazzaferri EL, Kloos RT. Current approaches to primary therapy for papillary and follicular thyroid cancer. J Clin Endocrinol Metab. 2001;86:1447-1462.
10. Eustatia-Rutten CF, Corssmit EP, Biermasz NR, et al. Survival and death causes in differentiated thyroid carcinoma. J Clin Endocrinol Metab. 2006;91:313-319.
11. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma: a study of the EORTC Thyroid Cancer Cooperative Group. Eur J Cancer. 1979;15:1033-1041.
12. Hay ID, Grant CS, Taylor WF, et al. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: a retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery. 1987;102:1088-1095.
13. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery. 1988;104:947-953.
14. Sherman SI, Brierley JD, Sperling M, et al. Prospective multicenter study of thyroid carcinoma treatment: initial analysis of staging and outcome. Cancer. 1998;83:1012-1021.
15. Greene FL, Page DL, Fleming ID, et al, eds. AJCC Cancer Staging Handbook: TNM Classification of Malignant Tumors, 6th ed. New York: Springer-Verlag, 2002.
16. Shaha AR. Implications of prognostic factors and risk groups in the management of differentiated thyroid cancer. Laryngoscope. 2004;114:393-402.
17. Davis NL, Bugis SP, McGregor GI, et al. An evaluation of prognostic scoring systems in patients with follicular thyroid cancer. Am J Surg. 1995;170:476-480.
18. Brierley JD, Panzarella T, Tsang RW, et al. A comparison of different staging systems. Predictability of patient outcome: thyroid carcinoma as an example. Cancer. 1997;79:2414-2423.
19. Chaplin JM, O'Brien CJ, McNeil EB, et al. Application of prognostic scoring systems in differentiated thyroid carcinoma. Aust NZ Surg. 1999;69:625-628.
20. Steinmuller T, Klupp J, Rayes N, et al. Prognostic factors in patients with differentiated thyroid carcinoma. Eur J Surg. 2000;166:29-33.
21. Passler C, Prager G, Scheuba C, et al. Application of staging systems for differentiated thyroid carcinoma in an endemic goiter region with iodine substitution. Ann Surg. 2003;207:227-234.
22. D'Avanzo A, Ituarte P, Treseler P, et al. Prognostic scoring systems in patients with follicular thyroid cancer: a comparison of different staging systems in predicting the patient outcome. Thyroid. 2004;14:453-458.
23. Yildirim E. A model for predicting outcomes in patients with differentiated thyroid cancer and model performance in comparison with other classification systems. J Am Coll Surg. 2005;200:378-392.
24. Lo CY, Chan WF, Kam KY, et al. Follicular thyroid carcinoma: the role of histology and staging systems in predicting survival. Ann Surg. 2005;242:708-715.
25. Kjellman P, Zedenius J, Lundell G, et al. Predictors of outcome in patients with papillary thyroid carcinoma. Eur J Surg Oncol. 2006;32:345-352.
26. Lo CY, Chan WF, Lang BH, et al. Papillary microcarcinoma: is there any difference between clinically overt and occult tumors. World J Surg. 2006;30:759-766.
27. DeLellis RA, Lloyd RV, Heitz PU, et al., eds. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours of Endocrine Organs. Lyon, France: IARC Press, 2004.
28. Lo CY, Chan WF, Lam KY, et al. Optimizing the treatment of AMES high-risk papillary thyroid carcinoma. World J Surg. 2004;28:1103-1109.
29. Lang BH, Lo CY, Chan WF, et al. Classical and follicular variant of papillary thyroid carcinoma: a comparative study on clinicopathological features and long-term outcome. World J Surg. 2006;30:752-758.
30. Brennan MD, Bergstralh EJ, van Heerden JA, et al. Follicular thyroid cancer treated at the Mayo Clinic, 1946 through 1970: initial manifestations, pathologic findings, and outcome. Mayo Clin Proc. 1991;66:11-22.
31. Pasieka JL, Zedenius J, Auer G, et al. Addition of nuclear DNA content to the AMES risk-group classification for papillary thyroid carcinoma. Surgery. 1992;112:1154-1160.
32. Akslen LA. Prognostic importance of histologic grading in papillary thyroid carcinoma. Cancer. 1993;72:2680-2685.
33. Schemper M, Stare J. Explained variation in survival analysis. Stat Med. 1996;15:1999-2012.
34. DeGroot LJ, Kaplan EL, McCormick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab. 1990;71:414-424.
35. Hay ID, Bergstralh EJ, Goellner JR, et al. Predicting outcome in papillary thyroid carcinoma: development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940 through 1989. Surgery. 1993;114:1050-1058.
36. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:418-428.
37. Noguchi S, Murakami N, Kawamoto H. Classification of papillary cancer of the thyroid based on prognosis. World J Surg. 1994;18:552-558.
38. Shaha AR, Loree TR, Shah JP. Intermediate-risk group for differentiated carcinoma of the thyroid. Surgery. 1994;116:1036-1041.
39. Lerch H, Schober O, Kuwert T, et al. Survival of differentiated thyroid carcinoma studied in 500 patients. J Clin Oncol. 1997;15:2067-2075.
40. Beeken S, Roye D, Weiss H, et al. Extent of surgery for intermediate-risk well-differentiated thyroid cancer. Am J Surg. 2000;179:51-56.
41. Ortiz Sebastian S, Rodriguez Gonzalez JM, Parilla Paricio P, et al. Papillary thyroid carcinoma: prognostic index for survival including the histological variety. Arch Surg. 2000;135:272-277.
42. Sugitani I, Kasai N, Fujimoto Y, et al. A novel classification system for patients with PTC: addition of the new variables of large (3cm or greater) nodal metastases and reclassification during the follow-up period. Surgery. 2004;135:139-148.
43. Greene FL. Cancer staging, prognostic factors, and our surgical challenges. Am Surg. 2005;71:615-620.
44. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid carcinoma. Thyroid. 2006;16:109-142.
45. Hundahl SA, Cady B, Cunningham MP, et al. Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996. U.S. and German Thyroid Cancer Study Group. An American College of Surgeons Commission on Cancer Patient Care Evaluation Study. Cancer. 2000;89:202-217.
46. Holzer S, Reiners C, Mann K, et al. Patterns of care for patients with primary differentiated carcinoma of the thyroid gland treated in Germany during 1996. U.S. and German Thyroid Cancer Group. Cancer. 2000;89:192-201.
47. Chow SM, Law SC, Au SK, et al. Differentiated thyroid carcinoma: comparison between papillary and follicular carcinoma in a single institute. Head Neck. 2002;24:670-677.
48. Lang BH, Lo CY, Chan WF, et al. Restaging of differentiated thyroid carcinoma by the 6th edition AJCC/UICC staging system: stage migration and predictability. Ann Surg Oncol. In press.
49. Kebebew E, Peng M, Reiff E, et al. Diagnostic and extent of disease multigene assay for malignant thyroid neoplasms. Cancer. 2006;106:2592-2597.
50. Wittekind C, Greene FL, Henson DE, et al., eds. TNM Supplement: A Commentary on Uniform Use, 3rd ed. New York: Wiley-Liss, 2003.